With a market capitalization (market cap) of $3.13B — a measure of how much the company is worth — TransMedics Group, Inc. is the 1772nd most valuable company in Healthcare as of August 18, 2026. Shares trade at $90.69, up +2.65% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Visit websiteAs of August 18, 2026, TransMedics Group, Inc. (TMDX) is worth $3.13B — this is its market capitalization, the total value of all its outstanding shares.
TransMedics Group, Inc.’s market cap is $3.13B, which ranks it #1772 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
TransMedics Group, Inc. (TMDX) shares trade at $90.69, up 2.65% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025
TransMedics Group, Inc. trades at a price-to-earnings (P/E) ratio of 16.2, based on its latest share price and annual earnings per share.